09.05.2018
Evotec AG DE0005664809
DGAP-News: EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE
DGAP-News: Evotec AG / Key word(s): Quarter Results
EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE
09.05.2018 / 07:01
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- 55% INCREASE IN GROUP REVENUES
- STRONG UNDERLYING OPERATIONAL PERFORMANCE WITH NEW BUSINESS MIX AFTER
APTUIT ACQUISITION
- "3X30" OUTLOOK FOR 2018 CONFIRMED
- WEBCAST AND CONFERENCE CALL TODAY AT 02.00 PM CEST
Hamburg, Germany, 09 May 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
reported financial results and provided corporate updates for the first
quarter of 2018.
GOOD FINANCIAL PERFORMANCE WITH NEW BUSINESS MIX
- Group revenues: 55% increase to EUR 79.0 m (Q1 2017: EUR 50.9 m);
EVT Execute revenues of EUR 78.5 m (Q1 2017: EUR 48.6 m);
EVT Innovate revenues of EUR 10.4 m (Q1 2017: EUR 12.5 m)
- Adjusted Group EBITDA up 4% to EUR 14.0 m (Q1 2017: EUR 13.4 m);
Adjusted EBITDA for EVT Execute of EUR 17.2 m (Q1 2017: EUR 12.4 m);
Adjusted EBITDA for EVT Innovate of EUR (3.2) m (Q1 2017: EUR 1.0 m)
- Group R&D expenses at EUR 4.6 m (Q1 2017: EUR 4.7 m)
- Solid liquidity position of EUR 78.5 m
EVT EXECUTE - HIGH QUALITY AND EFFICIENCY IN R&D
- Significant progress within ongoing alliances (e.g. start of third
clinical Phase I study in endometriosis with Bayer (after period-end))
- Aptuit integration according to plan
- Launch of INDiGO solution to accelerate drug candidate delivery; first
alliances established (e.g. Petra Pharma, Japanese company Carna Biosciences
(after period-end))
- New and extended integrated drug discovery and development agreements
- Expansion of CRISPR-based technology offering with licence from ERS
Genomics (after period-end)
EVT INNOVATE - FOCUS ON ACCELERATING INNOVATION
- In Q1 2018, as expected, no noteworthy milestones, but all key projects on
track
- Continued focus on expansion of iPSC platform and patient-centric
approaches
- Academic BRIDGE model gaining momentum: First project identified in LAB150
with MaRS Innovation, further three projects identified in LAB282 with
Oxford University
- Alliance with Sanofi to accelerate infectious disease R&D (close of
transaction expected in H1 2018)
CORPORATE
- Preparation to convert into European Company (SE)
FINANCIAL GUIDANCE 2018 CONFIRMED
1. GOOD FINANCIAL PERFORMANCE WITH NEW BUSINESS MIX
In the first quarter of 2018, Evotec's Group revenues grew to EUR 79.0 m, an
increase of 55% compared to the same period of the previous year (Q1 2017:
EUR 50.9 m). This increase resulted primarily from the strong performance in
the base business and the Aptuit contribution (EUR 25.3 m). Due to the
timing of milestones, revenues from milestones, upfronts and licences in Q1
2018 decreased to EUR 2.7 m (Q1 2017: EUR 6.2 m). Q1 2017 revenues were
driven by significant milestone achievements. The gross margin amounted to
23.4% in the first three months of 2018 (Q1 2017: 37.3%). This margin
decrease compared to the prior-year period primarily reflects a new business
mix following the most recent acquisition of Aptuit, amortisation, adverse
FX effects and the timing of milestones. Gross margin excluding amortisation
from M&A would be at 27.3%.
In the first quarter of 2018, Evotec's R&D expenses amounted to EUR 4.6 m
(Q1 2017: EUR 4.7 m) and were focused on first-in-class innovation mainly in
CNS, metabolic disease, oncology and academic BRIDGE initiatives. Selling,
general and administrative (SG&A) expenses increased as expected by 82% in
the first quarter of 2018 to EUR 13.3 m (Q1 2017: EUR 7.3 m) and are on a
similar level as in Q4 2017. This increase mainly results from expenses of
Aptuit for three months as well as an increase in headcount in response to
Company growth.
Adjusted Group EBITDA in the first quarter of 2018 increased to EUR 14.0 m
(Q1 2017: EUR 13.4 m). Evotec's operating result in the first quarter of
2018 amounted to EUR 6.5 m (Q1 2017: EUR 9.9 m). The Company's net result in
Q1 2018 amounted to EUR 3.5 m (Q1 2017: EUR 7.1 m) and decreased compared to
the prior year mainly due to increased amortisation resulting from the
purchase price allocations of recent acquisitions, adverse foreign currency
effects, milestone timing and the higher share of the loss of associates
accounted for using the equity method.
Liquidity, which includes cash and cash equivalents (EUR 57.3 m) and
investments (EUR 21.2 m) amounted to EUR 78.5 m as of 31 March 2018 (31
December 2017: EUR 91.2 m). This decrease reflects the repayment of loans,
increased capital expenditure, equity investments and bonus payments.
Revenues from the EVT Execute segment were EUR 78.5 m in Q1 2018 and
significantly increased compared to the prior-year period (Q1 2017: EUR 48.6
m). This increase is primarily attributable to growth in the base business
and a full three months Aptuit contribution. Also included in this amount
are EUR 9.9 m of intersegment revenues (Q1 2017: EUR 10.3 m). The gross
margin for EVT Execute was 20.8% and was affected, against the prior-year
period, by amortisation, the new business mix with a different margin
expectation in the Aptuit business, adverse FX effects and the timing of
milestones. In Q1 2018, the adjusted EBITDA of the EVT Execute segment was
very strong at EUR 17.2 m and significantly improved compared to the prior
year (Q1 2017: EUR 12.4 m).
Revenues from the EVT Innovate segment amounted to EUR 10.4 m (Q1 2017: EUR
12.5 m) and consist entirely of third-party revenues. EVT Innovate revenues
in Q1 2018 include lower milestone revenues than revenues in the prior-year
period. EVT Innovate generated a gross margin of 31.1%, which was affected
by adverse FX effects and the timing of milestones. R&D expenses for the EVT
Innovate segment were EUR 5.6 m in Q1 2018 (Q1 2017: EUR 5.8 m). The EVT
Innovate segment reported an adjusted EBITDA of EUR (3.2) m (Q1 2017: EUR
1.0 m). Adjusted EBITDA of EVT Innovate in Q1 2017 was driven by significant
milestone achievements of EUR 4.5 m, which were not expected in Q1 2018. All
key projects to achieve significant milestones in 2018 are on track.
2. EVT EXECUTE & EVT INNOVATE
EVT EXECUTE - HIGH QUALITY AND EFFICIENCY IN R&D
The first quarter of 2018 saw a strong operational performance by the EVT
Execute segment. The Aptuit integration into the Evotec Group is proceeding
according to plan. In March 2018, Evotec launched the INDiGO offering, which
was part of the strategic rationale behind the Aptuit acquisition. INDiGO is
the market-leading integrated drug development solution that accelerates
drug candidate delivery from candidate selection through to IND submission.
Shortly afterwards, Evotec entered into new INDiGO alliances, e.g. with
Petra Pharma and Carna Biosciences (Japan) (after period-end).
Furthermore, Evotec made significant progress within its ongoing alliances.
Another promising small molecule was advanced into Phase I for the treatment
of endometriosis in Evotec's strategic Bayer endometriosis alliance (after
period-end). Since the beginning of this collaboration, six
first-in-class/best-in-class non-hormonal pre-clinical candidates have been
generated, three of which have now advanced into Phase I clinical trials.
In addition and amongst other highlights, Evotec entered into new and
extended integrated drug discovery and development agreements in the first
quarter of 2018 and extended its CRISPR-based technology offering with a
licence from ERS Genomics after period-end.
EVT INNOVATE - FOCUS ON ACCELERATING INNOVATION
EVT Innovate also had a very good start into 2018. Evotec continues to place
a strong focus on its iPSC platform and the development of patient-centric
approaches. The academic BRIDGE model is also gaining momentum. A first
project was selected in LAB150 with MaRS Innovation, which was only
initiated in September 2017, and three additional projects were selected in
LAB282 with Oxford University (initiated in November 2016).
Furthermore, on 08 March 2018, Evotec announced that Evotec and Sanofi
entered into exclusive negotiations to accelerate infectious disease
research and development through a new open innovation platform led by
Evotec. This transaction is expected to close in the first half of 2018,
subject to finalisation of definitive agreements and completion of the
appropriate social process.
3. CORPORATE
PREPARATION TO CONVERT INTO EUROPEAN COMPANY (SE)
At the end of the first quarter 2018, Evotec announced its preparations for
legal conversion of the Company into a European Company (Societas Europaea,
SE). The proposal, which has already been approved by the Supervisory Board,
will be put to a vote at this year's Annual General Meeting on 20 June 2018.
The conversion reflects the continuing European and international focus of
the Evotec Group, which has grown considerably in recent years with
subsidiaries in France, Germany, Italy, Switzerland, the United Kingdom and
the USA.
4. FINANCIAL GUIDANCE 2018 CONFIRMED
Guidance 2018 Actual
2017
Group revenues More than 30% growth EUR 257.6
m
Adjusted Group Improve by approx. 30% compared to EUR 58.0
EBITDA1) 2017 m
R&D expenses Approx. EUR 20-30 m EUR 17.6
m
1) EBITDA is defined as earnings before interest, taxes, depreciation, and
amortisation of intangibles. Adjusted EBITDA excludes contingent
considerations, income from bargain purchase and impairments on goodwill,
other intangible and tangible assets as well as the total non-operating
result
Webcast/Conference Call
The Company will hold a conference call to discuss the results as well as to
provide an update on its performance. Furthermore, the Management Board will
present an outlook for the fiscal year 2018. The conference call will be in
English.
Conference call details
Date: Wednesday, 09 May 2018
Time: 02.00 pm CEST (01.00 pm BST/08.00 am EDT)
From Germany: +49 69 22 22 29 043
From France: +33 170 750 705
From Italy: +39 023 601 3806
From UK: +44 20 3009 2452
From USA: +1 855 402 7766
Access Code: 37969784#
A simultaneous slide presentation for participants dialling in via phone is
available at http://www.audio-webcast.com/, password: evotec0518.
Webcast details
To join the audio webcast and to access the presentation slides you will
find a link on our home page www.evotec.com shortly before the event.
A replay of the conference call will be available for 24 hours and can be
accessed in Europe by dialling +49 69 22 22 33 985 (Germany) or +44 20 3426
2807 (UK) and in the USA by dialling +1 866 535 8030. The access code is
654573#. The on-demand version of the webcast will be available on our
website: https://www.evotec.com/financial-reports.
NOTE
The 2017 and 2018 results are not fully comparable. The difference stems
from the acquisition of Aptuit, effective 11 August 2017. The results from
Aptuit are only included from 11 August 2017 onwards. The accounting
policies used to prepare the interim information are the same as those used
to prepare the audited consolidated financial statements for the year ended
31 December 2017.
From 01 January 2018 onwards, Evotec applies IFRS 15 in the financial year
2018. The comparison period in 2017 is also presented according to IFRS 15
in the quarterly statement, affecting data in the consolidated interim
statement of financial positions as well as in the consolidated interim
income statement.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic to meet the industry's need for innovation
and efficiency in drug discovery (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, diabetes and
complications of diabetes, pain and inflammation, oncology and infectious
diseases. On this basis, Evotec has built a broad and deep pipeline of more
than 80 partnered product opportunities at clinical, pre-clinical and
discovery stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and
development partnerships with Sanofi in the field of diabetes, with Pfizer
in the field of tissue fibrosis and with Celgene in the field of
neurodegenerative diseases. For additional information please go to
www.evotec.com and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Key figures first quarter 2018
Key figures of consolidated interim income statement
Evotec AG and subsidiaries
In TEUR except share data and per share data
January to March Chang-
e
2018 20171) in %
Revenues 78,984 50,911 55
Gross margin in % 23.4 37.3
Research and development expenses (4,616) (4,651) (1)
Selling, general and administrative (13,294) (7,314) 82
expenses
Other operating income (expenses), net 5,953 2,893
Operating result 6,531 9,922 34
Adjusted Group EBITDA2) 14,015 13,445 4
Net income 3,455 7,096 (51)
Weighted average shares outstanding 147,292,602 139,717,125
Net income per share (basic/diluted) 0.02 0.05
1) Prior-year data adjusted according to IFRS 15
2) Before contingent considerations, income from bargain purchase and
excluding impairments on goodwill, other intangible and tangible assets as
well as the total non-operating result
Segment information: First quarter 2018
First quarter of 2018
In TEUR
EVT EVT Intersegment Evotec
Execute Innovate eliminations Group
External revenues 68,565 10,419 - 78,984
Intersegment revenues 9,979 - (9,979) -
Gross margin in % 20.8 31.1 23.4
R&D expenses (142) (5,587) 1,113 (4,616)
SG&A expenses (11,524) (1,770) - (13,294)
Other operating income 5,275 678 - 5,953
(expenses), net
Operating result 9,968 (3,437) - 6,531
Adjusted EBITDA1) 17,163 (3,148) 14,015
1) Before contingent considerations, income from bargain purchase and
excluding impairments on goodwill, other intangible and tangible assets as
well as the total non-operating result
First quarter of 20171)
In TEUR
EVT EVT Intersegment Evotec
Execute Innovate eliminations Group
External revenues 38,364 12,547 - 50,911
Intersegment revenues 10,270 - (10,270) -
Gross margin in % 27.2 56.9 37.3
R&D expenses (222) (5,789) 1,360 (4,651)
SG&A expenses (5,816) (1,498) - (7,314)
Other operating income 1,987 906 - 2,893
(expenses), net
Operating result 9,158 764 - 9,922
Adjusted EBITDA2) 12,397 1,048 13,445
1) Prior-year data adjusted according to IFRS 15
2) Before contingent considerations, income from bargain purchase and
excluding impairments on goodwill, other intangible and tangible assets as
well as the total non-operating result
Key figures of consolidated interim statement of financial position
Evotec AG and subsidiaries
In TEUR
31 March 31 Dec Change
2018 20171) in %
Cash, cash equivalents and investments 78,510 91,156 (14)
Working capital 17,664 12,716 39
Current and non-current loan liabilities 182,802 189,928 (4)
Total stockholders' equity 339,285 332,674 2
Total assets 665,300 663,819
1) Prior-year data adjusted according to IFRS 15
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
09.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard);
Regulated Unofficial Market in Dusseldorf, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
684019 09.05.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT